A novel 7-azaisoindigo derivative-induced cancer cell apoptosis and mitochondrial dysfunction mediated by oxidative stress

Journal of Applied Toxicology

Volumn 31, Issue 2, 2011, Pages 164-172

  Xu, Jing jing ^a   Dai, Xiao min ^a   Liu, Hai liang ^a   Guo, Wen jie ^a   Gao, Jing ^a   Wang, Chao hui ^b   Li, Wen bin ^b   Yao, Qi zheng ^b  

^a JIANGSU UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

7 azaisoindigo derivative; Antitumor; Apoptosis; Mitochondria; ROS

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; CASPASE 3; CYTOCHROME C; INDOLE DERIVATIVE; N1 (N BUTYL) 7 AZAISOINDIGO; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG STRUCTURE; ENZYME ACTIVATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR MEMBRANE; MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; WESTERN BLOTTING;

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FREE RADICAL SCAVENGERS; HUMANS; INDOLES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEOPLASMS; OSMOLAR CONCENTRATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 79952001772     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1577     Document Type: Article

References (49)

1. Armstrong JS. 2007. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharm. 151: 1154-1165.
2. 2+-induced injury of rat ascites hepatoma AS-30D cells. Biochim. Biophys. Acta 1757: 1568-1574.
3. Chatterjee S, Kundu S, Bhattacharyya A. 2008. Mechanism of cadmium induced apoptosis in the immunocyte. Toxicol. Lett. 177: 83-89.
4. Costantini P, Jacotot E, Decaudin D, Kroemer G. 2000. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl Cancer Inst. 92: 1042-1053.
5. Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. 2001. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 20: 3786-3797.
6. Danial NN, Korsmeyer SJ. 2004. Cell death: critical control points. Cell 116: 205-219.
7. Debatin KM, Poncet D, Kroemer G. 2002. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21: 8786-8803.
8. Dias N, Bailly C. 2005. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem. Pharmacol. 70: 1-12.
9. Dirks AJ, Hofer T, Marzetti E, Pahor M, Leeuwenburgh C. 2006. Mitochondrial DNA mutations, energy metabolism and apoptosis in aging muscle. Ageing Res. Rev. 5, 179-195.
10. Droge W. 2002. Free radicals in the physiological control of cell function. Physiol. Rev. 82: 47-95.
11. Duensing S, Duensing A, Lee DC, Edwards KM, Piboonniyom SO, Manuel E, Skaltsounis L, Meijer L, Munger K. 2004. Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23: 8206-8215.
12. Fang J, Sawa T, Akaike T, Maeda H. 2002. Tumor-targeted delivery of polyethylene glycol-conjugated d-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 62: 3138-3143.
13. Galluzzi L, Larochette N, Zamzami N, Kroemer G. 2006. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25: 4812-4830.
14. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. 1999. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1, 60-67.
15. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. 2000. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407: 390-395.
16. Kantrow SP, Tatro LG, Piantadosi CA. 2000. Oxidative stress and adenine nucleotide control of mitochondrial pemeability transition. Free. Radic. Biol. Med. 28: 251-260.
17. Kim JS, He L, Qian T, Lemasters JJ. 2003a. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. Curr. Mol. Med. 3, 527-535.
18. 2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett. 274: 72-77.
19. Kim SC, Cho MK, Kim SG. 2003b. Cadmium-induced non-apoptotic cell death mediated by oxidative stress under the condition of sulfhydryl deficiency. Toxicol. Lett. 144: 325-336.
20. Kim SA, Kim YC, Kim SW, Lee SH, Min JJ, Ahn SG, Yoon JH. 2007. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin. Cancer Res. 13: 253-259.
21. Knockaert M, Blondel M, Bach S, Leost M, Elbi C, Hager GL, Nagy SR, Han D, Denison M, Ffrench M, Ryan XZP, Magiatis P, Polychronopoulos P, Greengard P, Skaltsounis L, Meijer L. 2004. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 23: 4400-4412.
22. Kumar B, Kumar A, Pandey BN, Mishra KP, Hazra B. 2009. Role of mitochondrial oxidative stress in the apoptosis induced by diospyrin diethylether in human breast carcinoma (MCF-7) cells. Mol. Cell. Biochem. 320: 185-195.
23. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L. 2001. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - a property common to most cycline-dependent kinase inhibitors? J. Biol. Chem. 276: 251-260.
24. Lee JW, Moon MJ, Min HY, Chung HJ, Park EJ, Park HJ, Hong JY, Kim YC, Lee SK. 2005. Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorg. Med. Chem. Lett. 15: 3948-3952.
25. Li DS, Das S, Yamada T, Samuels HH. 2004. The NRIF3 family of transcriptional coregulators induces rapid and profound apoptosis in breast cancer cells. Mol. Cell Biol. 24: 3838-3848.
26. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou NN, Gong YF, Wang HGH, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl Acad. Sci. USA 100: 11013-11018.
27. Liu HL, Xu JJ, Dai XM, Shi JB, Xu S, Gao J, Yao QZ, Liu F. 2009. Both DNA damage and mitochondrial dysfunction are involved in novel oxadiazolo[3, 4-d]pyrimidine nucleoside derivatives-induced cancer cell death. J. Appl. Toxicol. 29: 489-495.
28. Marko D, Schatzle S, Friedel A, Genzlinger A, Zankl H, Meijer L, Eisenbrand G. 2001. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 84: 283-289.
29. Morel Y, Barouki R. 1999. Repression of gene expression by oxidative stress. Biochem. J. 342: 481-496.
30. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R. 2005. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl Acad. Sci. USA 102: 5998-6003.
31. Pathak N, Khandelwal S. 2007. Role of oxidative stress and apoptosis in cadmium induced thymic atrophy and splenomegaly in mice. Toxicol. Lett. 169: 95-108.
32. Perabo FGE, Frossler C, Landwehrs G, Schmidt DH, Von Rucker A, Wirger A, Muller SC. 2006. Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res. 26: 2129-2135.
33. Phillipson JD. 1993. Chinese drugs of plant origin - chemistry, pharmacology and use in traditional and modern medicine. Phytochemistry 32: 1081-1081.
34. Pilkington GJ, Parker K, Murray SA. 2008. Approaches to mitochondrially mediated cancer therapy. Semin. Cancer Biol. 18: 226-235.
35. Pique M, Barragan M, Dalmau M, Bellosillo B, Pons G, Gil J. 2000. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett. 480: 193-196.
36. Ribas J, Bettayeb K, Ferandin Y, Knockaert M, Garrofe-Ochoa X, Totzke F, Schachtele C, Mester J, Polychronopoulos P, Magiatis P, Skaltsounis AL, Boix J, Meijer L. 2006. 7-bromoindirubin-3'-oxime induces caspase-independent cell death. Oncogene 25: 6304-6318.
37. Ribas J, Yuste VJ, Garrofe-Ochoa X, Meijer L, Esquerda JE, Boix J. 2008. 7-Bromoindirubin-3'-oxime uncovers a serine protease-mediated paradigm of necrotic cell death. Biochem. Pharmacol. 76: 39-52.
38. Szatrowski TP, Nathan CF. 1991. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51: 794-798.
39. Tsujimoto Y, Shimizu S. 2007. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12: 835-840.
40. Wang ZH, Li WY, Li FL, Zhang L, Hua WY, Cheng JC, Yao QZ. 2009. Synthesis and antitumor activity of 7-azaindirubin. Chin. Chem. Lett. 20: 542-544.
41. Wei YH, Lee HC. 2002. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp. Biol. Med. (Maywood) 227: 671-682.
42. Xiao ZJ, Hao YS, Liu BC, Qian LS. 2002. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 43: 1763-1768.
43. Xiao ZJ, Wang Y, Lu L, Li ZJ, Peng Z, Han ZC, Hao YS. 2006. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Leuk. Res. 30: 54-59.
44. Xie YB, Liu YL, Ma C, Yuan ZM, Wang WY, Zhu ZY, Gao GQ, Liu XG, Yuan HX, Chen RZ, Huang SJ, Wang XL, Zhu XN, Wang XM, Mao ZX, Li MT. 2004. Indirubin-3'-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci. Lett. 367: 355-359.
45. Yamaguchi H, Paranawithana SR, Lee MW, Huang ZW, Bhalla KN, Wang HG. 2002. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of bax conformational change in human breast cancer cells. Cancer Res. 62: 466-471.
46. Zamzami N, Marchetti P. 1995. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J. Exp. Med. 182: 367-377.
47. Zamzami N, Susin S, Marchetti P. 1996. Mitochondrial control of nuclear apoptosis. J. Exp. Med. 183: 1533-1544.
48. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. 2000. Role of BAX in the apoptotic response to anticancer agents. Science 290: 989-989.
49. Zhou YJ, Zhang SP, Liu CW, Cai YQ. 2009. The protection of selenium on ROS mediated-apoptosis by mitochondria dysfunction in cadmium-induced LLC-PK1 cells. Toxicol. In Vitro 23: 288-294.